{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:05:52Z","timestamp":1771542352729,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plaque psoriasis is a chronic skin condition characterized by skin scales. It causes a cosmetic problem for patients. Mirikizumab has shown promising results in managing psoriasis. Nevertheless, there remains a\u00a0dispute over its safety. This systematic review and meta-analysis aimed to assess the effectiveness of mirikizumab in individuals with plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched four databases: PubMed, Scopus, Cochrane CENTRAL, and Web of Science. We included trials comparing mirikizumab with placebo in psoriatic patients. Two independent authors extracted data in an Excel sheet. We used RevMan software (version 5.2) to perform meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A meta-analysis of three RCTs with a total of 1648 patients was performed. Mirikizumab showed significantly higher rates of PASI 75, PASI 90, and PASI 100 responses at week 16 compared to placebo, with risk ratios (RR) of 10.47, 11.5, and 25.94, respectively (all P\u2009&lt;\u20090.00001). According to adverse events, we found no difference between mirikizumab and placebo. Furthermore, mirikizumab showed significant results compared to placebo in terms of DLQI, sPGA, and body surface area, with P\u2009&lt;\u20090.00001. Unfortunately, there was no difference between the two groups regarding adverse events, with p\u2009=\u20090.63.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mirikizumab showed good responses in managing plaque psoriasis. However, additional clinical trials are required to verify its safety and evaluate its long-term efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00210-025-04416-0","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T10:11:39Z","timestamp":1752142299000},"page":"521-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does Mirikizumab benefit patients with plaque psoriasis? a systematic review and meta-analysis"],"prefix":"10.1007","volume":"399","author":[{"given":"Shrouk F.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed R.","family":"Abdelraouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Wagdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mena","family":"Essam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Elsekaily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"4416_CR1","doi-asserted-by":"publisher","unstructured":"Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz I Bin, Kurtzman DJB (2018) A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatol Treatment [Internet]. 29(6):569\u201378. Available from: https:\/\/doi.org\/10.1080\/09546634.2017.1422591","DOI":"10.1080\/09546634.2017.1422591"},{"issue":"6","key":"4416_CR2","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/bjd.21743","volume":"187","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Kimball AB, Augustin M, Okubo Y, Witte MM, Capriles CR et al (2022) Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)*. Br J Dermatol 187(6):866\u2013877","journal-title":"Br J Dermatol"},{"key":"4416_CR3","doi-asserted-by":"publisher","unstructured":"Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen YK et al (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator&#x2013;controlled VOYAGE 1 trial. J Am Acad Dermatol [Internet]. 76(3):405\u201317. Available from: https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"4416_CR4","doi-asserted-by":"crossref","unstructured":"Chat VS, Kearns DG, Uppal SK, Han G, Wu JJ (2022) Management of Psoriasis With Topicals: Applying the 2020 AAD-NPF Guidelines of Care to Clinical Practice. Cutis. Frontline Medical Communications Inc. 110:8\u201314.","DOI":"10.12788\/cutis.0573"},{"key":"4416_CR5","doi-asserted-by":"publisher","unstructured":"Cherubin M, Tebar WR, Meneghini V, Bensenor IM (2023) Psoriasis and associated risk factors: a cross-sectional analysis of the Brazilian Longitudinal Study of Adult Health.\u00a0Rev Assoc Med Bras 69(6):e20230038. Available from: https:\/\/doi.org\/10.1590\/1806-9282.20230038","DOI":"10.1590\/1806-9282.20230038"},{"key":"4416_CR6","doi-asserted-by":"crossref","unstructured":"Gisondi P, Bellinato F, Girolomoni G (2020) Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks. J Clin Med [Internet]. 9(11). Available from: https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3594","DOI":"10.3390\/jcm9113594"},{"key":"4416_CR7","doi-asserted-by":"publisher","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y et al (2018) Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet [Internet]. 392(10148):650\u201361. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(18)31713-6","DOI":"10.1016\/S0140-6736(18)31713-6"},{"issue":"2","key":"4416_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5217\/ir.2023.00043","volume":"22","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, Matsuoka K, Watanabe M, Hisamatsu T, Hirai F, Milata J et al (2024) Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies. Intest Res 22(2):172\u2013185","journal-title":"Intest Res"},{"key":"4416_CR9","doi-asserted-by":"publisher","unstructured":"Liu T, Li S, Ying S, Tang S, Ding Y, Li Y et al (2020) The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol. Available from: https:\/\/doi.org\/10.3389\/fimmu.2020.594735","DOI":"10.3389\/fimmu.2020.594735"},{"key":"4416_CR10","doi-asserted-by":"publisher","unstructured":"Magro F, Protic M, De Hertogh G, Chan LS, Pollack P, Jairath V, et al (2024) Effects of Mirikizumab on Histologic Resolution of Crohn\u2019s Disease in a Randomized Controlled Phase 2 Trial. Clinical Gastroenterology and Hepatology [Internet]. 22(9):1878\u20131888.e10. Available from: https:\/\/doi.org\/10.1016\/j.cgh.2023.11.010","DOI":"10.1016\/j.cgh.2023.11.010"},{"key":"4416_CR11","doi-asserted-by":"crossref","unstructured":"Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG (2021) Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatol Ther. Adis 11:385\u2013400.","DOI":"10.1007\/s13555-021-00483-2"},{"key":"4416_CR12","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Antes G, Atkins D et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6. Available from: https:\/\/doi.org\/10.1371\/journal.pmed.1000097","DOI":"10.1371\/journal.pmed.1000097"},{"key":"4416_CR13","doi-asserted-by":"publisher","unstructured":"Papp K, Warren RB, Green L, Reich K, Langley RG, Paul C et al (2023) Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study. Lancet Rheumatol [Internet]. 5(9):e542\u201352. Available from: https:\/\/doi.org\/10.1016\/S2665-9913(23)00120-0","DOI":"10.1016\/S2665-9913(23)00120-0"},{"key":"4416_CR14","doi-asserted-by":"publisher","unstructured":"Raharja A, Mahil SK, Barker JN (2021) Psoriasis: a brief overview. Clin Med 21(3):170\u2013173. Available from: https:\/\/doi.org\/10.7861\/clinmed.2021-0257","DOI":"10.7861\/clinmed.2021-0257"},{"issue":"1","key":"4416_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjd.17628","volume":"181","author":"K Reich","year":"2019","unstructured":"Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A et al (2019) Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol 181(1):88\u201395. https:\/\/doi.org\/10.1111\/bjd.17628","journal-title":"Br J Dermatol"},{"key":"4416_CR16","doi-asserted-by":"publisher","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B et al (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator&#x2013;controlled VOYAGE 2 trial. J Am Acad Dermatol [Internet]. 76(3):418\u201331. Available from: https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"4416_CR17","doi-asserted-by":"publisher","unstructured":"Rendon A, Sch\u00e4kel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20(6):1475. https:\/\/doi.org\/10.3390\/ijms20061475","DOI":"10.3390\/ijms20061475"},{"key":"4416_CR18","doi-asserted-by":"crossref","unstructured":"Salimi S, Yamauchi PS, Thakur R, Weinberg JM, Kircik L, Abdelmaksoud A et al (2020) Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review. Vol. 33, Dermatologic Therapy. Blackwell Publishing Inc.","DOI":"10.1111\/dth.13800"},{"key":"4416_CR19","doi-asserted-by":"crossref","unstructured":"Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L (2020) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.\u00a0Cochrane Database Syst Rev 1(1):CD011535","DOI":"10.1002\/14651858.CD011535.pub3"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04416-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04416-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04416-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:07:47Z","timestamp":1771538867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04416-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4416"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04416-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a meta-analysis, which did not require IRB approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}